Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab 3 mg/kg vs 10 mg/kg in metastatic chemotherapy-naive castration-resistant prostate cancer
2014-002987-34Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ipilimumab in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Radiologic Progression Free Survival. Started Sep 2014; status: terminated.
02
Drugs
ipilimumab
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2014-002987-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002987-34.